Furthermore, the inhibition of NR4A1 decreases cell growth and induces apoptosis in many cancer cells in vitro and in vivo, and NR4A1 inhibitors or antagonists are being characterized as a new class of antitumor agents for the treatment of solid tumors overexpressing this receptor [4,10,11]. Here, NR4A1 is linked to cancer.